2024-11-20 17:14:13
Author: Novavax, Inc. / 2023-07-23 23:37 / Source: Novavax, Inc.

Novavax to Participate in World Vaccine Congress Europe

Novavax to Participate in World Vaccine Congress Europe

GAITHERSBURG,Md.,Oct. 16,2021 --Novavax,Inc. (Nasdaq: NVAX),a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,today announced that Vivek Shinde,M.D.,Vice President,Clinical Development,will deliver a presentation during the World Vaccine Congress Europe 2021. A topic of discussion will be Novavax' COVID-NanoFlu™ Combination Vaccine,which combines the company's recombinant nanoparticleprotein-based COVID-19 and NanoFlu™ vaccine candidates with Matrix-M™ adjuvant in a single formulation.

Session details are as follows:

Date:

Wednesday,October 20,2021

Time:

11:30 a.m. – 12:00 p.m. Central European Time (CET) /


5:30 a.m. – 6:00 a.m. Eastern Daylight Time (EDT)

Title:

Update on Novavax' NanoFlu vaccine and COVID-19-NanoFlu Combination Vaccine development

Novavax Participant:

Vivek Shinde,Clinical Development

For more information or to register,visit the Congress website.

About Novavax


Novavax,Inc.(Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery,development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.Novavaxis conducting late-stage clinical trials for NVX-CoV2373,its vaccine candidate against SARS-CoV-2,the virus that causes COVID-19. NanoFlu™,its quadrivalent influenza nanoparticle vaccine,met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporateNovavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information,visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors


Novavax,Inc.


Erika Schultz | 240-268-2022


ir@novavax.com

Solebury Trout


Alexandra Roy | 617-221-9197


aroy@soleburytrout.com

Media


Ali Chartan | 240-720-7804


Laura Keenan Lindsey | 202-709-7521


media@novavax.com

Tags: Biotechnology Health Care/Hospital Infectious Disease Control Medical/Pharmaceuticals

Previous:

Next:

Leave a comment

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release